MedTrace Logo

Liposomal Bupivacaine and Transoral Robotic Surgery

NCT05862792 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2025-09-09

No results posted yet for this study

Summary

This study is for patients with oropharyngeal squamous cell carcinoma. We want to learn more about how we can optimize pain control in patients who undergo transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma. Our goal is to determine if a local anesthetic called EXPAREL® (Liposomal Bupivacaine) impacts postsurgical pain and swallow function in patients with oropharyngeal squamous cell carcinoma undergoing TORS. EXPAREL® is an FDA-approved anesthetic drug that provides long-lasting and precise pain relief when injected into the surgical wound. Our study team wants to determine if injecting EXPAREL® into the surgical wound will provide better pain relief and swallow function when compared to patients who do not undergo postoperative EXPAREL® injection. Both options for postoperative pain control are considered standard of care for patients undergoing TORS.

Conditions

  • Oropharyngeal Cancer
  • Dysphagia, Oropharyngeal
  • Post Operative Pain
  • Transoral Robotic Surgery

Interventions

DRUG

Liposomal bupivacaine

We will inject liposomal bupivacaine into the surgical bed.

Sponsors & Collaborators

  • Geisinger Clinic

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2025-12-31
Completion
2026-01-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05862792 on ClinicalTrials.gov